鼻窦炎、鼻息肉与正常鼻粘膜组织样本差异蛋白质组学研究

注册号:

Registration number:

ChiCTR-BOR-17011946 

最近更新日期:

Date of Last Refreshed on:

2017-07-11 20:56:15 

注册时间:

Date of Registration:

2017-07-11 00:00:00 

注册号状态:

预注册

Registration Status:

Prospective registration

注册题目:

鼻窦炎、鼻息肉与正常鼻粘膜组织样本差异蛋白质组学研究

Public title:

Differential proteomic study of nasal sinusitis, nasal polyps and normal nasal mucosa samples

注册题目简写:

English Acronym:

研究课题的正式科学名称:

鼻窦炎、鼻息肉与正常鼻粘膜组织样本差异蛋白质组学研究

Scientific title:

Differential proteomic study of nasal sinusitis, nasal polyps and normal nasal mucosa samples

研究课题代号(代码):

Study subject ID:

在二级注册机构或其它机构的注册号:

The registration number of the Partner Registry or other register:

申请注册联系人:

马莉 

研究负责人:

刘志强 

Applicant:

LI MA 

Study leader:

ZHIQIANG LIU 

申请注册联系人电话:

Applicant telephone:

+86 13510279552

研究负责人电话:

Study leader's
telephone:

+86 15986613913

申请注册联系人传真 :

Applicant Fax:

研究负责人传真:

Study leader's fax:

申请注册联系人电子邮件:

Applicant E-mail:

243319513@qq.com

研究负责人电子邮件:

Study leader's E-mail:

liuzhiqiang05312438@126.com

申请单位网址(自愿提供):

Applicant website(voluntary supply):

研究负责人网址(自愿提供):

Study leader's website(voluntary supply):

申请注册联系人通讯地址:

深圳市龙岗区深惠路地铁3号线吉祥站

研究负责人通讯地址:

深圳市龙岗区深惠路地铁3号线吉祥站

Applicant address:

Immunology Research Laboratory of Institute of ENT, 3004 Longgang Avenue, Longgang District, Shenzhen, Guangdong, China

Study leader's address:

Immunology Research Laboratory of Institute of ENT, 3004 Longgang Avenue, Longgang District, Shenzhen, Guangdong, China

申请注册联系人邮政编码:

Applicant postcode:

518172

研究负责人邮政编码:

Study leader's postcode:

518172

申请人所在单位:

深圳市耳鼻咽喉研究所

Applicant's institution:

Shenzhen Institute of ENT

研究负责人所在单位:

深圳市耳鼻咽喉研究所

Affiliation of the Leader:

Shenzhen Institute of ENT

是否获伦理委员会批准:

Approved by ethic committee:

Yes

伦理委员会批件文号:

Approved No. of ethic committee:

NO201702018

伦理委员会批件附件:

Approved file of Ethical Committee:

查看附件View

批准本研究的伦理委员会名称:

深圳市耳鼻咽喉研究所医学伦理委员会

Name of the ethic committee:

Medical Ethics Committee of ShenZhen Institute of ENT

伦理委员会批准日期:

Date of approved by ethic committee:

2017-06-11 00:00:00

伦理委员会联系人:

Contact Name of the ethic committee:

伦理委员会联系地址:

Contact Address of the ethic committee:

伦理委员会联系人电话:

Contact phone of the ethic committee:

伦理委员会联系人邮箱:

Contact email of the ethic committee:

研究实施负责(组长)单位:

深圳市龙岗区科技创新局

Primary sponsor:

Shenzhen Longgang district science and technology innovation commission

研究实施负责(组长)单位地址:

深圳市龙岗区清林中路海关大厦西座6楼

Primary sponsor's address:

Sixth floor, Custom Building, West Block, Qinglin Road, Longgang District, Shenzhen, Guangdong, China

试验主办单位(项目批准或申办者):

Secondary sponsor:

国家:

中国

省(直辖市):

深圳

市(区县):

Country:

China

Province:

Shenzhen

City:

单位(医院):

深圳市耳鼻咽喉研究所

具体地址:

深圳市龙岗区龙岗大道3004号

Institution
hospital:

Shenzhen Institute of ENT

Address:

3004 Longgang Avenue, Longgang District, Shenzhen, Guangdong, China

经费或物资来源:

深圳市龙岗区医疗卫生科技计划项目资助

Source(s) of funding:

Shenzhen Longgang district medical science and technology research project funding

研究疾病:

过敏性鼻炎  

Target disease:

Allergic rhinitis

研究疾病代码:

Target disease code:

研究类型:

57

Study type:

57

研究所处阶段:

其它 

Study phase:

N/A

研究设计:

随机抽样 

Study design:

Randomly Sampling 

研究目的:

1 探讨变应性鼻炎的发病机制;2 通过临床鼻窦炎、鼻息肉活检标本,质谱分析进行蛋白质组学研究;3 与正常鼻粘膜组织比较,特异性蛋白质功能研究  

Objectives of Study:

1. To investigate the pathogenesis of allergic rhinitis; 2. Proteomic analysis of nasosinusitis and nasal polyps biopsy specimens; 3. eludicate the role of specific protein in the nasosinusitis and nasal polyps.

药物成份或治疗方案详述:

 

Description for medicine or protocol of treatment in detail:

 

纳入标准:

Inclusion criteria

排除标准:

1 肾功能不全患者;2 怀孕或哺乳期的女性;3 治疗前3个月内接种过活疫苗者。

Exclusion criteria:

1. Patients with renal insufficiency;
2. Pregnant or lactating women;
3. Those who were vaccinated within three months.

研究实施时间:

Study execute time:

From 2017-07-11 00:00:00 To 2020-12-31 00:00:00  

征募观察对象时间:

Recruiting time:

From 2017-07-11 00:00:00 To 2020-12-01 00:00:00

干预措施:

Interventions:

组别:

术前

样本量:

30

Group:

before operation

Sample size:

干预措施:

保存组织活检标本

干预措施代码:

Intervention:

Save the biopsy specimens

Intervention code:

组别:

术后

样本量:

30

Group:

after operation

Sample size:

干预措施:

保存组织活检标本

干预措施代码:

Intervention:

Save the biopsy specimens

Intervention code:

组别:

对照

样本量:

20

Group:

control

Sample size:

干预措施:

保存组织活检标本

干预措施代码:

Intervention:

Save the biopsy specimens

Intervention code:

研究实施地点:

Countries of recruitment and research settings:

国家:

中国

省(直辖市):

广东 

市(区县):

 

Country:

China

Province:

Guangdong

City:

单位(医院):

深圳市耳鼻咽喉研究所 

单位级别:

深圳市重点实验室 

Institution
hospital:

Shenzhen Institute of ENT

Level of the institution:

Shenzhen key laboratory

测量指标:

Outcomes:

指标中文名:

鼻窦炎、鼻息肉与正常鼻粘膜组织蛋白质表达

指标类型:

主要指标

Outcome:

Protein exprand nasosinusitis nasal polyps and normal nasal mucosa tissues

Type:

Primary indicator

测量时间点:

测量方法:

Measure time point of outcome:

Measure method:

采集人体标本:

Collecting sample(s)
from participants:

标本中文名:

鼻窦炎、鼻息肉与正常鼻粘膜组织

组织:

Sample Name:

nasosinusitis nasal polyps and normal nasal mucosa tissues

Tissue:

人体标本去向

使用后销毁  

说明

Fate of sample:

Destruction after use  

Note:

征募研究对象情况:

Recruiting status:

正在进行

Recruiting

年龄范围:

Participant age:

最小 Min age 10 years
最大 Max age 60 years

性别:

男女均可

Gender:

Both

随机方法(请说明由何人用什么方法产生随机序列):

NA

Randomization Procedure (please state who generates the random number sequence and by what method):

NA

是否公开试验完成后的统计结果:

Calculated Results after the Study Completed public access:

公开/Public

盲法:

Blinding:

试验完成后的统计结果(上传文件):

Calculated Results after
the Study Completed(upload file):

是否共享原始数据:

IPD sharing

是Yes

共享原始数据的方式(说明:请填入公开原始数据日期和方式,如采用网络平台,需填该网络平台名称和网址):

2021-12 http://www.chictr.org.cn

The way of sharing IPD”(include metadata and protocol, If use web-based public database, please provide the url):

2021-12 http://www.chictr.org.cn

数据采集和管理(说明:数据采集和管理由两部分组成,一为病例记录表(Case Record Form, CRF),二为电子采集和管理系统(Electronic Data Capture, EDC),如ResMan即为一种基于互联网的EDC:

HIS system

Data collection and Management (A standard data collection and management system include a CRF and an electronic data capture:

HIS system

数据与安全监察委员会:

Data and Safety Monitoring Committee:

注册人:

Name of Registration:

 2017-07-11 20:56:15